Related Experiment Video
Updated: Oct 19, 2025

Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons
Published on: April 24, 2021
Multi-level inhibition of coronavirus replication by chemical ER stress
Mohammed Samer Shaban1, Christin Müller2, Christin Mayr-Buro1
1Rudolf Buchheim Institute of Pharmacology, Justus Liebig University, Giessen, Germany.
Abstract:
Coronaviruses (CoVs) are important human pathogens for which no specific treatment is available. Here, we provide evidence that pharmacological reprogramming of ER stress pathways can be exploited to suppress CoV replication. The ER stress inducer thapsigargin efficiently inhibits coronavirus (HCoV-229E, MERS-CoV, SARS-CoV-2) replication in different cell types including primary differentiated human bronchial epithelial cells, (partially) reverses the virus-induced translational shut-down, improves viability of infected cells and counteracts the CoV-mediated downregulation of IRE1α and the ER chaperone BiP. Proteome-wide analyses revealed specific pathways, protein networks and components that likely mediate the thapsigargin-induced antiviral state, including essential (HERPUD1) or novel (UBA6 and ZNF622) factors of ER quality control, and ER-associated protein degradation complexes. Additionally, thapsigargin blocks the CoV-induced selective autophagic flux involving p62/SQSTM1. The data show that thapsigargin hits several central mechanisms required for CoV replication, suggesting that this compound (or derivatives thereof) may be developed into broad-spectrum anti-CoV drugs.
Insights
Thapsigargin, an ER stress inducer, effectively inhibits coronavirus replication by targeting key viral mechanisms. This finding suggests thapsigargin as a potential broad-spectrum antiviral drug for coronaviruses (CoVs).
Area of Science:
- Virology
- Cell Biology
- Pharmacology
Background:
- Coronaviruses (CoVs) pose significant threats as human pathogens.
- Currently, no specific antiviral treatments are available for CoVs.
Purpose of the Study:
- To investigate the potential of pharmacological reprogramming of ER stress pathways to suppress CoV replication.
- To identify specific molecular mechanisms underlying the antiviral effects of thapsigargin.
Main Methods:
- Utilized thapsigargin, an ER stress inducer, to treat cells infected with various CoVs (HCoV-229E, MERS-CoV, SARS-CoV-2).
- Assessed viral replication, cellular viability, translational shut-down, and expression of ER stress markers (IRE1α, BiP).
- Performed proteome-wide analyses to identify host factors involved in the antiviral response.
Main Results:
- Thapsigargin efficiently inhibited CoV replication across different cell types, including primary human bronchial epithelial cells.
- The compound reversed virus-induced translational shutdown, improved cell viability, and counteracted CoV-mediated downregulation of IRE1α and BiP.
- Proteomic analysis identified ER quality control factors (HERPUD1, UBA6, ZNF622) and ER-associated degradation complexes mediating the antiviral state; thapsigargin also blocked CoV-induced autophagic flux.
Conclusions:
- Thapsigargin targets multiple critical mechanisms essential for CoV replication.
- This ER stress inducer demonstrates potential as a broad-spectrum antiviral agent against coronaviruses, warranting further development of thapsigargin or its derivatives.
Related Concept Videos
Chemical Agents for Microbial Control
Other Stress Responses in Bacteria
Effects of Chemicals: Overview
Enzyme Inhibition

